| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Surgery Branch, National Cancer Institute, Bethesda, Maryland
Requests for reprints: Jehad Charo, Surgery Branch, National Cancer Institute, NIH, Building 10, Center Drive, Bethesda, MD 20892. Phone: 301-496-9383; Fax: 301-496-0011; E-mail: j.charo{at}mdc-berlin.de.
Although immunotherapy based on the adoptive transfer of tumor-specific T lymphocytes has been shown to result in dramatic clinical responses in some patients, the relatively low levels of engraftment and persistence of the adoptively transferred cells may limit these responses in many patients. In an attempt to develop strategies for prolonging the survival of adoptively transferred T cells, we have carried out studies in which T cells obtained from healthy donors as well as tumor-specific T cells were transduced with a retrovirus expressing the human Bcl-2 gene. Our results indicate that these transduced T cells overexpress Bcl-2, are resistant to death, and have a survival advantage following interleukin-2 withdrawal compared with control T cells transduced with a retrovirus expressing green fluorescent protein. Tumor-specific T cells overexpressing Bcl-2 maintained their ability to specifically recognize and respond to target cells. Furthermore, we show that adoptive immunotherapy of an established B16 tumor can be significantly enhanced by overexpressing Bcl-2 in melanoma-specific T-cell receptor transgenic T cells. Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells.
Key Words: Human • Tumor Immunity • T Lymphocytes • Apoptosis • Gene Therapy
This article has been cited by other articles:
|
|
 |
|
  H. Norell, T. Martins da Palma, A. Lesher, N. Kaur, M. Mehrotra, O. S. Naga, N. Spivey, S. Olafimihan, N. G. Chakraborty, C. Voelkel-Johnson, et al. Inhibition of Superoxide Generation upon T-Cell Receptor Engagement Rescues Mart-127-35-Reactive T Cells from Activation-Induced Cell Death Cancer Res., August 1, 2009; 69(15): 6282 - 6289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rivera, N. Collins, M. T. Stephan, L. Lipuma, I. Leiner, and E. G. Pamer Aberrant Tissue Localization of Fungus-Specific CD4+ T Cells in IL-10-Deficient Mice J. Immunol., July 1, 2009; 183(1): 631 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Cheung, M. J.P. DuPage, H. K. Dong, J. Chen, and T. Jacks Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer Cancer Res., November 15, 2008; 68(22): 9459 - 9468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kruschinski, A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, and J. Charo Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas PNAS, November 11, 2008; 105(45): 17481 - 17486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hsu, S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P. D. Peng, X. Shen, T. J. Gomes, et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene Blood, June 15, 2007; 109(12): 5168 - 5177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Friedlein, F. El Hage, I. Vergnon, C. Richon, P. Saulnier, Y. Lecluse, A. Caignard, L. Boumsell, G. Bismuth, S. Chouaib, et al. Human CD5 Protects Circulating Tumor Antigen-Specific CTL from Tumor-Mediated Activation-Induced Cell Death J. Immunol., June 1, 2007; 178(11): 6821 - 6827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Charo and P. F. Robbins Contrasting effects of FLIPL overexpression in human T cells on activation-induced cell death and cytokine production J. Leukoc. Biol., May 1, 2007; 81(5): 1297 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Tsai, W.-S. Yeow, A. Chua, R. M. Reddy, D. M. Nguyen, D. S. Schrump, and D. M. Nguyen Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin Mol. Cancer Ther., December 1, 2006; 5(12): 2977 - 2990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. T. Joncker, J. Helft, A. Jacquet, V. Premel, and O. Lantz Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion. Cancer Res., May 15, 2006; 66(10): 5443 - 5451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Song, X. Tang, K. M. Harms, and M. Croft OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen J. Immunol., September 15, 2005; 175(6): 3534 - 3541. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
